Akums Drugs shares rose sharply on Monday to hit a 52-week high after the company reported strong Q1 FY27 results. Revenue rose 13.9% year-on-year, while profit increased 55%. EBITDA grew 35.4%, supported by strong performance in its CDMO business. The stock has gained 67% so far this year.